• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
NewslettersThe Capsule

Coronavirus is (literally) shaking up how the world moves

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
April 2, 2020, 5:45 PM ET

Happy Thursday, readers. And welcome to the first edition of The Capsule, formerly known as Brainstorm Health Daily. This is Sy, your writer then and now.

You’re getting this email because you subscribed to Brainstorm Health Daily. You can expect everything in The Capsule to be the same—new look, same great taste. As I mentioned to you all on Monday, we’re switching the newsletter to a weekly format, at least for the time being. You’ll get this newsletter in your inbox on Thursday afternoons ET.

Now onto our public health crisis… We’ve all become used to reading some bizarre headlines in these times. But I’m not sure anyone quite expected this.

My colleague Chris Morris, citing a fascinating study by Belgian scientists reported in the journal Nature, explores how the lockdowns and stay-at-home orders necessitated by coronavirus may have literally slowed down the movement of the globe (at least in certain regions).

The reason? A halt in human activity and transportation which has cut down on “seismic noice,” the vibrations which, en masse, extend to the crust of our planet itself.

You may be wondering, wait, is that good or just another element of concern? As it turns out, it could be quite helpful for geoscientists whose jobs are to detect earthquakes, volcanic activity, and the various tectonic shifts of our pale blue dot.

Read on for the week’s news, and see you again next Thursday.

Sy Mukherjee
sayak.mukherjee@fortune.com
@the_sy_guy

DIGITAL HEALTH

New coronavirus tests are on the way. The COVID-19 diagnostics situation is shifting rapidly. Here are just a few updates from the past week (and I'll have a much broader set of pieces to share on this soon): Henry Schein announced it would begin distributing a rapid antibody coronavirus blood test for current and past cases which it says can deliver results in just 15 minutes at the point of care; Abbott Labs has what it says is a five-minute point-of-care test that will be first be deployed in Detroit; the Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) to Cellex which can detect antibodies in people who have recovered from COVID-19; at-home genetic testing specialist Color is building a new lab to handle coronavirus testing with the goal of being able to manage 10,000 tests per day in the coming weeks; and that's just a few of the recent developments. This has become an all-hands-on-deck effort.

INDICATIONS

Sanofi says it can produce millions of doses of a coronavirus treatment. French drug giant Sanofi tells Reuters it will be able to offer millions of doses of the anti-malarial drug hydroxychloroquine (which has been touted on multiple occasions by President Trump as a promising drug candidate) should it prove successful in clinical trials. And within the latter point lies the rub—the decades-old treatment has decidedly limited evidence as a COVID-19 treatment and could cause serious side effects in certain patients. Overuse of the medicine could also limit its supply for malaria patients. (Reuters)

THE BIG PICTURE

A ventilator shortage meets a specialist shortage. There's been a significant supply chain problem when it comes to protective medical equipment, particularly the ventilators essential to helping COVID-19 patients. There are many reasons for that—but even beyond the bottleneck, there's another issue at hand: A lack of medical specialists who can even use the ventilators available to them. “We already have a shortage of nurses and physicians in the United States,” Marcus Schabacker, CEO of ECRI, a patient-safety nonprofit organization, told my colleagues Maria Aspan and Naomi Xu Elegant. (Fortune)

Three insurance giants say they'll waive coronavirus-related out-of-pocket costs. At least three major insurers—Aetna, Humana, and Cigna—have announced they'll waive certain out-of-pocket costs borne by patients for COVID-19 treatment. In essence that means COVID-19 patients with qualifying health plans wouldn't have to pony up money for coronavirus treatment; but, given that a multi-day hospital stay is more expensive for insurers than it is for patients (insurance companies usually have to begin providing a larger share of coverage costs after someone hits their deductible, which may happen quickly with an extended hospital visit), this is also likely a PR move that could be followed up for a request for government funding to stem losses. (NPR)

REQUIRED READING

Hospitals are running low on the most critical supply of all—oxygen, by Jeremy Kahn

A record 6.6 million apply for unemployment benefits, by The Associated Press

Commentary: After coronavirus, we need to rethink densely populated cities, by Joel Kotkin

Sign up for other Fortune newsletters.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Newsletters

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Newsletters

The startup that wants to give surgeons X-ray vision
NewslettersTerm Sheet
The startup that wants to give surgeons X-ray vision
By Allie GarfinkleApril 30, 2026
3 hours ago
Google Cloud CEO Thomas Kurian at Fortune Brainstorm AI 2025 in San Francisco. (Photo: Stuart Isett/Fortune)
NewslettersFortune Tech
Google Cloud is almost one-fifth of Alphabet’s business
By Andrew NuscaApril 30, 2026
4 hours ago
The $665 billion question: Will Big Tech’s AI gamble pay off?
NewslettersCEO Daily
The $665 billion question: Will Big Tech’s AI gamble pay off?
By Diane BradyApril 30, 2026
6 hours ago
How JPMorgan’s CIO is reshaping work at the bank with a $19.8 billion annual tech and AI budget
NewslettersCIO Intelligence
How JPMorgan’s CIO is reshaping work at the bank with a $19.8 billion annual tech and AI budget
By John KellApril 29, 2026
22 hours ago
They want their teams to win. The Liberty and Nets owners are funding scientific breakthroughs on human health that only billionaire philanthropy can  achieve
NewslettersMPW Daily
They want their teams to win. The Liberty and Nets owners are funding scientific breakthroughs on human health that only billionaire philanthropy can achieve
By Emma HinchliffeApril 29, 2026
22 hours ago
OpenAI is ‘strongly positioned,’ says Wedbush’s Dan Ives
NewslettersCFO Daily
OpenAI is ‘strongly positioned,’ says Wedbush’s Dan Ives
By Sheryl EstradaApril 29, 2026
1 day ago

Most Popular

Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
Success
Apple cofounder Ronald Wayne—whose stake would be worth up to $400 billion had he not sold it in 1976—says that at 91, he has no regrets
By Preston ForeApril 27, 2026
3 days ago
Jamie Dimon gets candid about national debt: ‘There will be a bond crisis, and then we’ll have to deal with it’
Economy
Jamie Dimon gets candid about national debt: ‘There will be a bond crisis, and then we’ll have to deal with it’
By Eleanor PringleApril 29, 2026
1 day ago
‘They left me no choice’: Powell isn’t going anywhere—blocking Trump from another Fed appointee
Banking
‘They left me no choice’: Powell isn’t going anywhere—blocking Trump from another Fed appointee
By Eva RoytburgApril 29, 2026
20 hours ago
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
AI
‘The cost of compute is far beyond the costs of the employees’: Nvidia executive says right now AI is more expensive than paying human workers
By Sasha RogelbergApril 28, 2026
2 days ago
‘Take the money and run’: Johns Hopkins economist Steve Hanke on why the UAE quit OPEC
Energy
‘Take the money and run’: Johns Hopkins economist Steve Hanke on why the UAE quit OPEC
By Shawn TullyApril 29, 2026
1 day ago
Google Cloud revenue is now 18% of Alphabet's business. Is this the beginning of the end of Google's search identity?
Big Tech
Google Cloud revenue is now 18% of Alphabet's business. Is this the beginning of the end of Google's search identity?
By Alexei OreskovicApril 29, 2026
13 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.